Conmed (CNMD) Asset Writedowns and Impairment (2021 - 2022)

Conmed (CNMD) posted Asset Writedowns and Impairment of $500000.0 for Q2 2022, down 44.38% on a QoQ basis from $899000.0 in Q3 2021.

Conmed (CNMD) Asset Writedowns and Impairment (2021 - 2022) Analysis & Trends

Conmed's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $500000.0 for Q2 2022.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $500000.0 in Q2 2022, while the trailing twelve-month figure through Sep 2023 was $500000.0 (down 64.26% YoY) and the FY2025 annual result came in at $363000.0, changed N/A from the prior year.
Asset Writedowns and Impairment was $500000.0 for Q2 2022 at Conmed, down from $899000.0 in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $899000.0 in Q3 2021 and bottomed at $500000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn
10	Conmed	1.33 Bn	1.29 Bn	183.45 Mn

Download Data